China Sustain2 Location RFP

SUSTAIN2 Location RFP 2018 Request for Proposal

DRAGON SKIN XS2 PRODUCTION PLANT ICON THEROPUETICS

I. Summary

Request for Proposal Sustain2 is seeking a location partner proposal for the location of 3 business operations in 2018.

1. Dragon Skin’s, X2 plant (“Dragon Skin”) 2. Icon Therapeutics’ clinic and regenerative medicine lab 3. AirShip Transport Systems (“AirShip”) Identifying location partners for both Dragon Skin and Icon Therapeutics represents Sustain2’s priority for this second quarter 2018.

AirShip production location partner selection is targeted for 4th quarter 2018.

Investment Economics Table 1. shows combined location numbers and impact benefits for Dragon Skin and Icon Therapeutics’ new location community

Sustain2 Portfolio Initiatives Viewing Sustain2’s location needs in the larger picture of Sustain2’s other business interests, including AirShip will support a better understanding of Sustain2 as a partner as well as future location project prospects. See Reference Gallery Item No. 4 Additional Portfolio Opportunities.

2

Icon Health & Education China’s aggressive ambitions to establish Private-Public Partnerships and a global standard in health care and education offers a complement to Icon’s mission. See Resource Gallery Item No. 1. The Case for China.

Icon Therapeutics’ commitment to establishing new standards in health care, providing training for over 1,800 therapeutic professional specialists while serving over 40,000 patients, reinforce this complement. China holds an opportunity to leverage its current lack of therapeutic infrastructure and limited number of trained clinicians towards a leadership position in this area of health globally.

China, not having a legacy infrastructure attached to dated ways of doing things, has an advantage of applying the scientific findings directly to clinical practice with a predominantly “blank slate advantage. Icon’s fortuitous timing to help set the standards in therapeutic care that could help China establish this lead is very promising. See Resource Gallery Item No. 4. A Level 3 Development Evolution

Transportation AirShip and Hyper Sub both hold clear first-in-class standing in their industries as represent disruptive transportation technologies. HyperSub exceeds world records for a sub’s speed and can be operated without an expensive support ship due to its unique ability to travel above the water surface to a dive point or destination. AirShip’s unique design takes current drone vertical-take-of-and-landing (VTOL) flight endurance, from at best 3 to 4 hours but typically less then 40 to 90 minutes, to 5 days of autonomous flight.

Additionally, both represent transitions into the future of transportation and subsurface missions.

Donald C. Winter, 74th Secretary of the Navy after extensively examining HyperSub said “with HyperSub we are looking at the future of naval warfare”. AirShip’s VTOL design scaled for transport and cargo loads represent opportunities for piloted and autonomous air taxi, troop, cargo, medivac and equipment transport.

Discussions of Level 3 applications on Sustain2 companies are emphasised by including discussions in this blue background text box.

Protection & Security With over 30 million USD in back orders to Chinese customers, Dragon Skin’s X2 is Sustain2’s first production priority in a series of armor protection and security solutions.

3

Level 3 Sustain2 business plan for both Dragon Skin and Icon Therapeutics assumes a strong R&D investment to preserve its first in class status lead. Effort has been taken in picture selections and content to introduce both the current products as well as future design concepts. Review Gallery Item No. 4, Level 3 Development Evolution, also introduces how for each company there is yet a third evolution jump (“Level 3�) opportunity. An emerging 3rd Industrial Revolution impact is reshaping the world for both health care and protection and security. The impact of the exponential growth in computation power and scientific discovery suggests third level growth in across almost every industry.

RFP Response Sustain2 interest in identifying the right location partner goes beyond the search for a partner able to address some of the more traditional foreign investor incentives for which areas of interest to Sustain2 have been tabled in Reference Gallery Item No. 3, Issues in RFP Response.

Local Partner Capital Contributions

Of obvious priority interest to Sustain2 is a location partner’s willingness and ability to financially co-invest in the estimated Local Partner Capital Costs of USD 26.5 million (See Table 1.) to help offset location costs and take a stake in the game interest.

Sustainability Return

Sustain2 believes each project stands on its own in its ability to offer a significant economic and societal contribution to its new home community. This includes more than the 1,200 Jobs, 5.7 USD Billion in direct new economic contribution. Sustain2 is also interested in the humanitarian and community sustainability returns as well as shared rewards of business success.

Non-Monetary Considerations

There are other non-economic factors that will support critical venture success. Support in policy, establishing a strong China market, community development that will draw productive employees and technical talent are all examples of non-monetary considerations. Having a location partner that is significantly invested financially in each ventures success Sustain2 believes while help offset risk factors towards assuring its location success.

4

Outline

Reference Gallery

Request for Proposal

I. Summary p.2

II. Background p.6

III. Business Reviews p.8

IV. Location P24

1. The Case for China..............27

2. The Nature of China’s Need……………29

3. A Level 3 Development Evolution……35

4. Additional Portfolio Opportunities...39

5. Private-Public Partnership….47

6. Supplemental Picture Gallery…48

7. Index……………57

5

II. Background

Sustain2 Assets Sustain2, a British Virgin Island holding company, seeks to facilitate the next stage development for a number of health, education & technology enterprise assets, each that promise market disruptive innovations.

Location Partners This Sustain2 Location Partner RFP (Request for Proposal) provides several business summaries and invites a location partner seeking to benefit from the economic stimulus and investment return Sustain2 enterprises bring to respond with a proposal. Reference Gallery No. 3 Items in RFP Response introduce items of interest to Sustain2 in selecting the right location partner.

Purpose This RFP is not an open or public invitation but is made on a confidential and private invitation. IT is offered to selected recipient’s perceived as ready to offer specific foreign investment incentives for the establishment of the Dragon Skin X2 production plant, the X2 materials R&D centre and Icon Therapeutics services and regeneration lab.

“capable of touching a billion people’s lives”

Sustain2’s Mission Sutain2’s mission in its sampling of portfolio company presented here. Towards a new more sustainable world, Sustain2 embraces business solutions that meet three objectives: 1. an economical return on investment that meets Sustain2 risk rewards assessment 2. a strong humanitarian return on investment 3. an iconic standard to either directly or indirectly draw market emulation capable of touching a billion lives.

AHEAD Foundation AHEAD is both a forward looking word and an acronym for Advancing Health, Education and Development. With 1927 beginnings, the AHEAD Foundation has a heritage that goes back close to a century in fostering healthcare and educational development. Now contributing over 500 million USD a year in direct economic contributions from operating costs and employing over 10,000

6

educational and healthcare services employees servicing disproportionately Southern Asia communities, AHEAD initiatives offer a global reach in human empowerment and sustainability.

While AHEAD Foundation is a not-for-profit private foundation, as a mission expansion objective, Sustain2 represents it’s for-profit holding facility to develop and house enterprises in the sectors of Health & Education and Technology. AHEAD’s holds both legacy health and education assets, investments in targeted strategic initiatives including Sustain2’s global portfolio assets, that combined represent a total of over 4 billion USD in real estate holdings and enterprise value opportunities.

Sustain2’s Foreign Investment Location Partner Economics

Location Partner 10 Year Estimated Benefits

Currency in USD

Direct Enterprise Revenue

5.743 Billion

Compensation to Employees

259.4 Million

Jobs creation Direct and Indirect

4,136

Jobs created Direct

1,270

ICON Patients Served

40,000

World Class Materials and Bioscience R&D Labs Regenerative Medical Tourism Sales from out of Market

2 340 million

Jobs calculation extrapolated from Sustan2’s business model and referenced 1 Job Creation studies.

1 Direct jobs are taken from each business plan and industry benchmark references. Indirect jobs assumption journal references: Indirect Job Creation amongst IFC Clients, International Finance Corporation, World Bank

Group. Published October 2012 Regions identified Africa, Ukraine, Bangladesh, Indonesia and India ranging from ratios of 3:1 to 24:1, Indirect to Direct respectively https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=9&cad=rja&uact=8&ved=0ahUKEwi079Tvza3aAhXH61MKHTGQDMg QFgiFATAI&url=https%3A%2F%2Fwww.ifc.org%2Fwps%2Fwcm%2Fconnect%2Fa3d90b004cf855d686e5c7f81ee631cc%2FJobs%2Bstudy %2Bmicrocase%2Bstudiesctober%2B4final.pdf%3FMOD%3DAJPERES&usg=AOvVaw1YBI0GFT1ICHLJHT40xu3K, and 2014-2015

Direct Jobs & Livelihoods inclusive of Supply Chain across 484 Business in Africa and South Asia, published CDC

7

III. Business Review

This section reviews the three businesses eligible for relocation in 2018 including Icon the two, Therapeutics and Dragon Skin, for which respondents to this RFP are invited to address.

Health & Education

Icon Therapeutics

Icon Therapeutics Mission

Icon Therapeutics provides therapy treatment services and professional car giver training addressing delayed development disorders including specialty skilled care around the needs of the autistic child.

Icon Therapeutics revenue is generated from clinic centric professional training, clinical care and lab research and clinical services. Icon Therapeutics is the delivery of a care model where the clinical setting integrates four primary activities as fundamental to clinical care:

Group Plc, UK Development Finance Institution (DFI) Department for International Development http://www.cdcgroup.com/documents/measuring%20total%20employment%20effects.pdf

8

1. Specialty Trained Professionals resourced clinical sessions, offering collaborative Speech & Language, Physical and Occupational therapist, Neurology, Nutrition, Pediatric Nutritionist and other health disciplines 2. Scientific Research and Science Influenced Treatment Protocols

3. Post Graduate Professional Ongoing Training

4. Through integration with Sustain2’s affiliate US clinical practices, Icon Therapeutics therapists offer clinical services with US licensed supervisory oversight. Whether through rotating US licensed staff at China clinics or through remote medicine technology a child can benefit from a clinical experience and a US multi-disciplined staff.

Health & Education Iconic Standards

Icon branded projects represents iconic enterprises who so differentiate themselves in how they conduct business that they draw the industry to aspire to emulate setting a new standard of care and patient expectations. Iconic businesses represent a strong enough disruptive force and new level in quality of care and patient outcomes that the market is compelled to follow and transform how the market experiences their services and industry. Through remarkable life impact of the best care possible and a practice the industry is compelled to emulation, Icon is able to reach beyond the limited number of clinicians it can train or the patients they can see directly and drive industry change impact.

Icon Therapeutics is committed to an iconic change in the field of therapeutics that integrate the collaboration of specialty trained clinicians that is considered the desired standard in the West but remains not yet generally available in Asia therapeutic practice due to the general absence of specialty training.

Science Applied A post-modern, Flexner level of change (see Reference Gallery No. 4. A Level 3 Development Evolution), is not just a significant historical benchmark. Nor does it just point to a desired more science and academically more rigor influenced future. It is a

9

challenge for today. Icon Therapeutics is a clinical practice and professional training canter that offers a professional clinic centric training that integrates into clinical practice the current findings of science research both in therapist training and practice protocols. It is about resourcing the clinician to be able to absorb the fast pace of clinical practice change new research and science findings warrant.

US Supervisory Support.

•

Multi-Discipline Supervision

A multi-discipline representations of specialty medical doctors and 3 or more years post graduate trained therapeutic specialists primarily only available from the West today. Through affiliation with Sustain2 western affiliates, Icon

•

Technology & Science Applications

Icon Therapeutics makes matching commitment of economic investment and professional resource allocation to identifying and applying current best practices demanded to participate in the next level of care. Through integrating into the clinical treatment plan the findings of a review of each clinical case against the research, the use of technology, big data informatics and computational evaluations.

•

Neurology and neuro-feedback Therapies

Integrating physician staff in the treatment plan design, execution and both outcomes and progress evolutions bring a wider understanding of clinical challenge as well as empirical contributions to early diagnostic efforts and the efficacy of Neuro-Feedback Therapeutics.

10

To reach beyond human empathetic care, as important as it is, Icon Therapeutics’ commitment to a continues reach for a higher level of new care models that leverage new science and research solutions, Icon Therapeutics opens up the rewarding world of reaching beyond care to cures (See Resource Gallery Item No. 4, A Level 3 Development Evolution). Stem cell treatments and genomic therapies are at the heart of curative focused care.

Genetic Therapy Frontiers - Am erican longev ity advo cate ra ises a wa ren ess of 9 f ront iers of gen et ic therap eutics that ho ld p rom ise in h ea lth span. Ad dressin g cha llen ges asso cia ted with a ging and age asso ciat ed d iseases: St em C ell Exhau st ion, Altered Int ercellula r Com mun icat ion , Deregu lat ed Nut rient- Sensing, Mito chond ria l Dy sfu nct ion, C ellu la r S en escen ce, G eno mic Instab ility , Telo m ere Att rition , Ep igen et ic A lt eratio ns, Lo ss of Pro teo stasis.1

Longevity Therapeutics American Longevity advocate and CEO of BioViva identifies the early targets of genetic therapies her company hopes to address first in plans to open five clinics in 2019 strategically placed around the world. Her work in genetic therapy public awareness is continuing to build a demand for safe relevantly low cost treatments to the early stage genomic therapies priced in the range of USD 200,000 to 2,600,000.

As the world continues a demographic aging it also continues a trend of a widening of the income spread. The prospects of gracefully aging with even a piece of the vitality of youthful energy and health, or what has become called anti-aging, is a growing market and likely to fund much of the early stages of genomic therapeutics. Reputable and safe sources of clinical care appear to offer

11

strong economic prospects for clinics able to bring science new offers of treatment and cure. Staying market prepared as government agencies and the science community validate safety and efficacy in genomic understanding of disease and curative therapies is moving from what was once thought of as nonsensical to prudent and ethical business.

Emerging Market Opportunities Emerging on the market today is a growing demand for genomic therapies. While today

stem cell therapies hold the most attention in the autism spectrum disease categories genetic therapy still feels like it is in the research only stage. However, to underestimate the advance rate of science today deserves caution. Therapies that felt 10-20 years away just two years ago are bringing curative solutions and a new chance of life with new cures at a growing pace. In the US, 2017 has been the first year these treatments have crossed that threshold moving from clinical research experiments to medicines delivered to the general public.

In business it becomes necessary to plan for where the market will be, not where it is at the time of establishing business design. The front edge of genetic therapies is particularly growing momentum in the field of health span, often referred to as longevity. From a business perspective it pays to pay attention to where the market demand is in order to participate in underwriting the designs for the future.

Capital Resources

Insert viral “look mom, no cancer for 5 years now� sign pic

A willingness of capital sources to invest in the field of longevity research and genomic therapeutics is growing as both safety and efficacy continues to becomes more established. The opportunity to generate research funding from a growing segment of the capital market is escalating.

The news of new scientific developments in longevity continue to surface influenced significantly by those wanting to take advantages of the anticipated therapies yet during their life time. The industry is getting a reputation of being where capital chasses few credible efforts at serous research. As more and more "I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most stem cell and genetic engineering therapies gain devastating and intractable illnesses," says FDA FDA2 approval and treatments show low side effects and even Commissioner Scott Gottlieb. Dec 2017 curative outcomes the

2 United States Food and Drug Administration. There are over 1200 patients undergoing genetic

therapies in the US by FDA approval according to Liz Parish during her podcast interview with Sustain2 CEO Don Ashlock in June of 2017. Car T-Cell Genetic Therapy has now crossed the 5 year mark of complete remission for patients participating in early clinical trials. Many clinicians are preferring to refer to outcomes as cures, instead of remission, for patients who without any apparent negative side effects once faced life threatening cancer not effected by radiation, chemo therapy or other conventional treatment.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm

12

consumers’ confidence and apatite is only expected to swell.

Further, as China continues to grow its reputation for offering a treatment environment that is more promising in overcoming the challenges of translational medicine bearers, grows as a leader in investments in genetic sequencing, data analytics and strong public sector investments in scientific study and genomic research, the value of Icon Therapeutics China based operations will likely attract research capital.

The Icon Therapeutics Location Numbers

Icon Therapeutics

Impact

Icon Revenue

230 Million USD

Compensation to Employees

104 Million USD

Jobs creation Direct and Indirect (70d-2018, 281d-2028)

2816

Clinic Size

33,000 sq. ft.

Regenerative R&D Lab

17,000 sq.ft.

Professional Graduates

2070

Regenerative Revenue Sales from out of Market

340 million

Icon Patients Served World Class Materials and Bioscience R&D Labs

40,000 2

Cascade Care Model Integration Icon Therapeutics relocation business plan is designed along a spectrum of care models. These models represent a cascading of care models for children facing Autistic spectrum disorders starting closest to the child’s home. Prioritizing the model that offers the objective of the child remaining the most integrated into general society life, Icon Therapeutics has identified eight models of care from China opportunities. The Shenzhen Helping Hands clinic opened in June of 2017, an Outpatient Clinic, the 5th care model on the following list. The Icon Therapeutics Clinic & Regenerative Medicine Lap of interest to this RFP represents a start towards Sustain2’s next level or care in China by integrates a mix of the 5th, 7th and 8th in this cascade of care models: 1.

2.

3.

4.

Virtual AI Assisted Diagnostic and Therapeutic Support Home Health visits, care giver training and tele-medicine Integrative k-12 Enquiry Based Education Model Retreat Intensive Care Giver Training and Community Education

5. Hospital and Outpatient Medical Clinic Care 6. Residence Homes

13

7. Training Hospital Multidiscipline Integrative Care 8. Research Institute Clinical Trial Centres

14

Technology & Manufacturing

Hyper-Sub

Among Sustain2 technology assets ready for production design, manufacturing and commercial deployment is the manned/unmanned Hyper-Sub. The Hyper-Sub is a high speed, long range surface craft as well as diesel electric submarine. It is a straight forward combination of a speedboat (whose hull is flooded during a dive) with a proven deep dive cylindrical submersible.

15

Competitive options without its proprietary design technology are dependent on surface support vessels typically an additional 100 to 150 million USD investment, 100 plus additional support crew limiting dramatically the economic feasibility of missions and opportunity for stealth presence. This allows the Hyper-Sub to operate at only a fraction of the cost of other systems that are capable of accessing the subsea environment.

As a speedboat, the Hyper-Sub deploys very easily and quickly from almost any dock or beach, and can operate in as little as 3 feet of water. It is able travel long distances in most weather conditions while being able to do so without the aid of a transport or support vessel. It has a maximum utility range of 500 miles and a top speed of in excess of 30kts.

As a submarine, the HyperSub can dive to a maximum depth of 1,500 feet and is capable of diving repeatedly when deployed given its ability to recharge its batteries unlike its submersible counter parts. It carries a maximum of 6 crew members, can remain

16

submerged for up to 1 week and has a maximum lift capability of 30,000 pounds. The Hyper-Sub can remain deployed for many days while either on the surface, submerged, or in any combination of the two.

Unmanned it could remain submerged ready for underwater access and/or deployment for effectively an indefinite period of time.

Municipal and Government HyperSub Service Development Lab

Research & Development, Production and Port & Border Water Surface & Subsurface Protection

17

Dragon Skin Sustain2’s is ready to install a new state of the art, high capacity manufacturing and materials development facility to address China market sales for its X2 model. Dragon Skin has earned its reputation as the only fail safe nonpenetrable body armor. It’s flagship body armor product, Dragon Skin, was invented in 1996. This patented technology has proven to be technologically superior in every respect to its competition and has never suffered a tactical failure in the field. No other tactical body armor can make the same claim.

Dragon Skin Background

Dragon Skin Body Armor first gained acceptance beginning in the early 2000’s among special operation military teams on the Korean Peninsula. Its reputation grew, and Dragon Skin became the body armor-of-choice of America’s elite: CIA and other intelligence agency teams, the Secret Service Presidential Protection detail, military special forces, Department of Energy protective teams, at least nine senior generals in the Iraq and Afghanistan combat theaters, private contractors in the same operational areas, and law enforcement SWAT units all over the U.S. Developments in body armor over the last thirty years are numerous, but very few actually have revolutionized the industry. DRAGON SKIN® is a quantum leap in technology and the first and only practical, FLEXIBLE BODY ARMOR that is capable of defeating rifle rounds. The armor flexes and molds to the contours of your body (offering the first real female fit solution) and allows for significant greater coverage

18

than a rigid 10" x 12" plate that is the typical coverage offered in current technology that questions even the competitive product viability.

Material & Related New Science R&D

Material science is today on a fast evolution offering a verity of new component options that validate the importance of including an integrative materials sciences research lab to support specific client specification, product development and application requirements.

Already, recent material science investments by Sustain2 offer the anticipation of improved comfort, lower weight and cost savings for the same or superior protection. Integration with other technologies including smart helmets with vision, robotic and transport support AI supplements, body temperature regulation, exoskeleton bio-enhancements from external command, drone and internet expanded vision and beyond canopy intelligence and biometric and bio-informatics sample R&D objectives in new product designs. Additional product lines addressing the hardening of extra soldier assets such as vehicle, dwelling and key canopy support resources and integration with transport and drone resources will also be key areas of research for product application expansion.

Local Partner.

As the primary product in a line of armor protection technologies, Dragon Skin offers a disruptive enterprise ready business and needs a location that can support its global brand, help build new product iteration, market demands and policy support in China and desired global markets while supporting with labor, supply chain and transport logistics a high volume production facility able to address the immediate 2018 30 Million USD back order production requirements and future manufacturing demands

19

AirShip

AirShip’s patented fuselage lift and power production platform represent a quantum leap in performance with its endurance capabilities to operate a contiguous 5-day mission.

100% power demands on the V-5 configuration falls within 20% of its real time solar power production capacity leaving as much as 80% of its power production as a resource for high power demanding payloads such as on board computation, intelligence, communication such as satellite Wi-Fi and cellular communications and surveillance tasks.

Through capacitor electrical power storage and onboard hydrogen electrical generators, night time and under water submersible missions are possible.

The 5-day endurance ability allows AirShip to penetrate market sectors that have been unavailable to the current drone and UAV markets. Mission examples include trans-ocean, trans-continental, large border patrol and long mission applications including extended subsea on-call from long term underwater storage. New service economies are reached such as 24/7 large canopy cell-phone-on-demand for real time rescue, communications or surveillance services to mention a few. AirShip AirServe can serves millions of internet-based 1st Responder customers simultaneously with realtime data-in-motion mobile applications. Police, fire, search and rescue, emergency management, emergency communications, departments of transportation, public health departments and the news media represent target applications.

AirShip Transport Systems and AirShip Technology Group address manufacturing and design applications respectively. Sustain2 expect to select its AirShip Transport Systems manufacturing facilities location partner in 2018 for both its drone and transport models.

AirShip V9 and V17 VTOL UAVs will be designed as Tier II manned/unmanned vertical takeoff and landing transport craft for medium altitude and long endurance (MALE) transport with both local street and airways instant conversion ability. The aircrafts are designed thus for diverse mission deployment. The V9 is designed to carry cargo and/or two people. As a UAV, the V17 will be designed to provide transportation for 1-5 people with or without a pilot and is scalable up and down based on mission needs. The V-2 with a .6-meter wing span and the V-30 with a wing span of 9.1 meters address small drone applications too industrial and crew transport missions that could relocate critical assets by shipping container lift ability.

20

When used as a military transport vehicle it is ideal for transport to forward operating bases (FOB); drive on prepared surfaces or off-road conditions; take off and land vertically to cross water, terrain or obstructions and avoid ambush or Improvised Explosive Devices (IEDs). The design has speed, maneuverability and range to perform "tactically relevant" missions on a single tank of fuel. The aircraft added mission extensions include: •

medium altitude stationary hover surveillance

•

communications relay

•

ship-to-shore troop insertion

•

improvised explosive device (IED) avoidance

•

Special Operations Forces resupply

•

medical evacuations, and

•

remote payload emplacement.

The AirShip V9 and V17 will use two turbo strut engines to power the three ducted fans. This clean tech hybrid fuel-toelectric propulsion enables the UAVs to acquire fuel in the field for resupply as well as benefit from solar film surface power production.

The AirShip Endurance VTOL UAV lateral and rear turbines are a combination ducted fan with integrated Solar Turbine Air Accelerators (compressed air) that support the UAV clean tech propulsion system. Both electric propulsion systems can be used simultaneously or independently. For low acoustics stealth flight, only the integrated air accelerators are enabled.

These solar turbines provide thrust propulsion required by the UAV vertical takeoff and landing (VTOL), consume dramatically less energy during forward fixed wing flight operation, and fly with a 5-day flight endurance. With its efficient design, this patent pending AirShip Endurance VTOL UAV quickly operates flight management and delivers sustainable propulsion via applied external solar film, a hydrogen fuel cell, and internal rechargeable ultra-capacitors for stored electricity.

21

AirShip Design & Materials Lab

There are a lot of opportunities to utilize new materials and step forward with the application of new technologies when designing a solution from the ground up. Forward engendering opportunities include both electrical circuit integrated 3D printed carbon fiber integrating layered composite battery infused energized carbon fiber frame, panel and fuselage components. Design evolutions can address mew technologies, energy production, storage and a growing applications expanded in part by the growing developmemts in material sciences and new energy pulpusion that have come to justify design modifications in real time, representing design changes to orders as they come in. Most significantly is the opportunity to leverage significant design work already materilized enough to date to justify the option of parrllel development of atonomous and piloted manned and cargo payload applications in the 3 to 9 meter wing span models.

The “Flying Ray” patented fuselage lift and power production platform integrated into the AirShip airframe design offers one of several key disruptive design outcomes of which deriving its ability to provide an unprecedented endurance is most notable. This following day and night sequence striped endurance comparison table places the endurance capacity of up to an unprecedented 3 months’ flight without landing endurance design goals for AirShip for 3 of its models including the V2 and V5 in a vertical left access as the second design compared to other major market options plotted with a red line to their respective endurance characteristics of less than one hour to up to 5 years (Titan Solara). It could be argued that the Titan Solara with it’s extremely limited performance options should not be integrated into a comparison table for its tactical limits and non-VTOL capabilities. Yet in its extended endurance it builds confidence that engineering innovation has crossed the barrier to long lasting flight options before the AirShip Flying Ray design. The market comparisons below the AirShip listings represent craft that exemplify at least many of the other broad range of application and flight characteristics including VTOL flight ability that are present in AirShip’s huge application envelop. Still the endurance delta makes it so disruptive as illustrated.

22

23

IV. Location

Facilities Icon Therapeutics § § §

Clinic & Professional Training School – 33,000 sq. ft.

Lab – 17,000 sq. ft.

Medical Tourism Reception Centre - 20,000sq. ft.

Dragon Skin § § §

Production Facilities- 100,000 sq. ft.

Materials Lab- 25,000 sq. ft.

Transition Pre-order Production – 15,000 sq. ft.

24

Incentives Incentives offered by a responding government to this RFP are sought in order to help offset Sustain2’s initial capital outlays and ongoing operational costs with location and represent the primary factor in selecting a new project operational and production location.

A

Development Capital

A.1

Economic Development Bonds

A.2

Local Strategic Equity Partners

A.3

Employee Salary Subsidies

A.4

Social Services Financial Support

A.5

Banking & Investment Banking Resources Loan Support

B

Facilities

B.1

Tennant Improvement

B.2

Operation & Production

B.3

Staff Housing

B.4

Residential & Community Resource Developments

Sustain2 recognizes that the right match with a location partner where combined strengths can be a maximized can have critical impact on our companies’ success. As any partnership it justifies the same give and take inherent in any partnership.

Identified here are key incentive areas that a new location partner may wish to address as items that hold some precedent in incentives to encouraging a company to choose a location partner. However, creativity and a fresh look at identifying strengths unique to any location is welcomed.

C C.1 D

Labor - Recruiting, Hiring, Training, HR Services Employee Leasing Services Tax Incentives & Financial

D.1

Employee

D.2

Corporate Tax Rate - Holiday

D.3

Access to Foreign Exchange

D.4

Trade Protection

25

D.5

Exemptions

E

Market Development

E.1

China’s Policy and as a Public Customers

E.2

Domestic Market

E.3

Reginal & International Influence

F

R&D Support

F.1

Municipal or Affiliate University Resource Sharing

F.2

Development & Research Grants

G

Quality of Life Indicators

While capital resources to share in the cost of company capitalization by a local partner and the related capital costs may hold the highest value in establishing a mutual investment.

Incentive extended by a location partner to the continued operating success are also important. Assistance in Policy, identification of government as well as private contracts and networking assistance in the reach for supporting marketing and sales efforts to drive future revenue, establishing pre-opening sales, each represent examples of where some creativity on the part of a local partner to leverage its resources and connections may be an important in creating a preferred location partner for Sustain2.

26

Resource Gallery

No. 1. The Case for China

Health & Education Delivery Models

China’s Reform Opportunity

China’s commitment to innovation, private partnerships, science and health and education reform is strong.3 This comes at an important evolution stage as science and technology’s emerging impact on health and education is globally supported with exponential growth.

New scientific understanding and solutions also meet at the intersection of Sustain2’s portfolio interests to demonstrate new models and standards of therapeutic care and professional care giver training. With less legacy investments more common in the West, China’s also favors a fresh environment more suited for current science deployment in a new level of clinical care and clinical and educational integrated special education. China’s environment for reform and appetite for aggressive deployment comes without many of the transitional barriers to adoption of clinical practice born of recent scientific findings.

In China, autism is classified as a disability. Funding of education services for kids with autism from impoverished families has increased in recent years, and by the end of 2020, the central government aims to financially support 80 percent of children with autism, including those over the age of 7, who did not qualify for financial support before.

3 http://mp.weixin.qq.com/s/Rybnt9ViC1aP3FE2LCtiSg 【特别关注】教育部逐一回复政协委员关于特殊教育的提案：都是热点问题，说了不白说！（一） 2018-03-12

27

But access to special education remains an issue, despite new regulations requiring public schools to develop better services for children with disabilities. There’s no clear pathway or time frame for achieving this goal, and experts have criticized the regulations for stopping short of guaranteeing access to education for children with disabilities.

Although public schools are required to maintain a certain quota of children with disabilities, the number is so low that private institutions remain the only option for the majority, explained 4 Jia Meixiang, deputy director of the Beijing Association for Rehabilitation of Autistic Children .

A Need for Standard of Care Models

Following a 2017 investigative trip of a China delegate investigating care resources in the US, Sustain2 received an invitation from a China economic development office in Chongching to bring care models identified in the US to China. Sustain2’s has begun negotiations with China domestic partners to help establish a standard of care in therapeutic services and professional training through Sustain2’s ICON Health & Education initiatives. The opportunities to respond to the needs for China do not represent a small undertaking. Multiple care and financial models of care have been researched from both a child needs centric and enterprise level and visits with potential China operational partners, regulators and policy makers have been explored extensively.

Critical to the success of clinical and educational intigrated solutions to a child’s development needs is the reform and development of new models in both ecucation as well as clinical and theroputic care. China’s continued commitment to opening up to global influences that can support the Chines charictoristics that have fosterd its society strengths and investing in reform along with the size of their need creating both a motivation and a more fundamental platform to build from, make a case for China’s destiny and opportunity to seaze a global lead.

4 http://www.sixthtone.com/news/1000161/chinas-autism-schools-a-last-resort-for-youth-on-the-spectrum

28

Resource Gallery

No. 2. The

Nature of China’s Need

China’s Reform Opportunity China’s commitment to innovating and reform spell a future of solutions that are not simply of value to China future alone. Especially during this time while China lays the foundations for One Road One Belt and in policy and spirit grow a powerful influence in their intent on being a global influencer for change.

China’s choices in educational and health reform as it relates to the development needs of its children and the Autistic child share a response to a global growing challenge.

Should from China great need come the will power to forge iconic examples in new models of care that embrace child centric therapeutics and education, the escalating emergence of new science and technology based solutions, present a resolve to address the

China recognizes both its need for reformation in health care and general its population misunderstanding of diseases.

Three-year-old Zhang Jia died at a Chinese center for autistic children which uses punishing exercise regimes to treat what it regarded as the Autism cause, as a disease of the "rich and lazy". Taxing exercises to rid kids of the natural body reaction to perspire included 12 miles of walking a day in heat while winter clothing clad and water drinking regime to cause urination at least hourly and daily incubation to “cure them” of sweating.

9 million children face a 2 year waiting list for treatment in China, an Jia’s mom felt they were desperate with no other place to send their child who was sent across the country to the center that charged $5,000 every three months of a 21-month course saying “For us, at least it provided a glimmer of hope”.

The treatment centers medical director Mr. Xia is quoted “There are more and more autistic children because we are better off than before and we treat children as ‘little emperors,’” found in his book Notes on the Rehabilitation of Children with Autism a glaring indication of the ignorance of basic medical knowledge and understanding of autism.

“Parents become the slaves of children. Children from this kind of family become sick easily, and can easily become autistic,” the book instructs. For a claim of credibility, he refers to his own conclusions that more than 99 percent of autistic families surveyed by Mr. Xia were from white collar or rich families.

29

shortfall in understanding and professional care giver training, China’s need will share space with iconic opportunity.

Understanding China’s Need

Understanding China’s need for a new standard in professional training and clinical care is a multi-front challenge.

The Size and Scope of Need First it includes understanding the scope of need and the quantity of care required suggesting the need for 10-20 medium size clinics for every 500,000 in population.

The Nature of the Need Second it includes understanding the significant knowledge and understanding of the disease to be addressed and what represents appropriate science and evidence based care and matching professional training for care givers. A proper understanding of the need for adequate professional training yields conclusions for a multi-speciality disciple approach requiring a Western level developed speciality training of at least the three major disciplines of Speech and Language Therapist, Occupational Therapy and Physical Therapy coupled with a strong mix of neurological, notational, genetics and psychological Medical Doctor level trained physicians along with accompanied allied health trained and licensed specialty technicians. Some health challenges require a complex and comprehensive approach to care and early stage diagnostic resources.

30

Jia’s Story By extreme contrast, the story of little Zhang Jia illustrates these issues in just one story as well as the significant distance China needs to travel towards these goals.5 See text box embedded telling of Jia’s story.

Of course Jia’s story stands in stark contrast to the qualified medical trained physicians that can be found throughout China especially in city children’s hospitals. But even in a city hospital, it is not uncommon for the tending physician’s day to be plagued with hundreds of patients to see in a single long shift, with only time to focused on first visit diagnostics due to a lack of needed speciality trained therapeutic support staff. What support staff they have to actually pursue treatment programs are often trained to with 2 years of education beyond secondary school, typically five years short of global standards for developed nations. Little resources exist to address the 1st Level of a therapeutic care treatment plan inspired from China’s deep history of viable mystic traditions nor the science informed specialty care of the 2 Level of care born of the 20th century. Physician training at qualified modern universities still don’t generally support the specialty areas of therapeutic care and the need to get the science and technology based informed treatment solutions of the 3rd revolution era now on us in stem cell and genomics is yet further out of reach.

The lack of knowledge and understanding with patient parents and family care givers is a constant struggle as well as that they prefer to challenge and deny the diagnostics findings of the physicians for social reasons. Instead it is still too prevalent that visits to the hospital include parents insisting that a tragic procedure be given, having the child's tonged cut or that the child be connected to shock and muscle contraction electrodes that can still be found on the mired of pseudo techno therapeutic gadgets on the market today.

The Exponential Increase for Therapeutic Services

Thirdly it is hard to get a grasp of the growth the challenge of a growing rate of new diagnosed cases well require in increased demand on the health care system. This is illustrated best by the challenge of Autistic care alone. Hope is built in indications of genetic, AI and stem cell related diagnostics, care and even cures but until they can represent wide application the near future demand is daunting. So much so it is likely to foster faster adoption of new science based curative solutions, scalable approaches to leveraging new telemedicine technologies and new care models.

5 https://www.telegraph.co.uk/news/2016/05/07/autistic-boy-3-dies-after-punishing-exerciseat-china-centre/ , http://www.sixthtone.com/news/811/toddler-jia-jias-death-highlightsautism-ignorance , http://www.straitstimes.com/asia/east-asia/guangzhou-probes-autisticboys-death and http://www.chinanews.com/sh/2016/0504/7857439.shtmlhttp://www.chinanews.com/sh/2016/05-04/7857439.shtml

31

The Nature of Health Reform Health care has seen dramatic changes through disruptive iconic initiatives to bring change. The past in this regard offers a promise of a bright future.

The Flexner Report This transformation was illustrated, perhaps better than any other example, in the transition experienced by medical professional training in the US by changes that followed the Flexner Report in 1910, still studied by every medical student today. A collection of 7 education institutions at high risk of survival changed their destiny and that of medicine in the early 20th century through two collaborating donors committed to a higher establishing a new standard they hoped would be emulated globally, and it was.

Up to the time the medical profession training was primarily the passing on of clinical traditions as practices of care by particulars offering a mentor role to the next generation who typically had little more than a primary education. It was not a desired profession nor respected. Ignorance characterized both the clinician and the patient, absent familiarity with both education rigors or understanding of the scientific process. While strong in clinical experience it was based primarily on folk lore. Professional functioned without fundamental understanding of diseases treated never mind evidence based care efficacy or emerging sciences findings. Today we know the schools worldwide. Harvard, Vanderbilt, John Hopkins and Stanford are among them. The way they transitioned professional training was either later emulated by the other medical schools or they went out of business. Now 100 years later such disruptive and iconic transitions are again possible in global health and education. At a time of exponential growth in both Autism and the rate of development of stem cell and genomic sciences that dominate its future models of care, the therapeutic practice sector in China, holds both the will and the potential of duplicating the impact medicine experienced in the early 20th century.

Science Foundations

Professional education reform will be at the heart of a new era for health sciences. But it will be more driven by the element of exponentially expanding computational capacities then textbook, lab and clinic instruction. AI, genomics, genetic therapies, pharmaco-genetics, quantum computation, Nano technologies, quantum physics, augmented reality, cell regeneration, new evolutions in scanning, robotics, informatics diagnostics, electronic monitored accountability, outcomes and treatment design, stem cell and bio-science discoveries now bring a new technological factor into clinician training and practice.

32

6

关于政协十二届全国 委员会第五次会议 第 1216 号（教育类 112 号）提案答复的函 教提案〔2017〕第 257 号 您提出的“关于加 快发展我国特殊儿童教 育的提案”收悉，经商 国家发展改革委、财政 部和中国残联，现答复 如下： 党中央、国务院 高度重视特殊教育，党 的十八大提出“支持特殊教育”，十八届三中全 会要求“推进特殊 教育改革发展”，十八届五中全会要求“办 好特殊教育”。教育部会同相关部门，按照党中 央、国务院的决策部署，2014—2016 年实施 了《特殊教育提升计划（2014—2016 年）》 （以下简称《一期计划》），2017 年又启动实 施《第二期特殊教育提升计划（2017—2020 年）》（以下简称《二期计划》），加大力度 推进特殊教育改革发展，不断提高普及水平、 保障能力和教育教学质量。

About the Fifth Session of the 12th National Committee of the Political Consultative Conference

The "Proposal on Accelerating the Development of Special Children's Education in China" as received by you has been received. The National Development and Reform Commission, the Ministry of Finance, and China Disabled Persons' Federation of Business are now replying as follows:

The Party Central Committee and the State Council attach great importance to special education. The party's 18th National Congress proposed "support for special education." The Third Plenary Session of the 18th CPC Central Committee called for "advancement of special education reform and development". The Fifth Plenary Session of the 18th CPC Central Committee called for "perfect special education." The Ministry of Education, together with relevant departments, implemented the “Special Education Promotion Plan (2014-2016)” (hereinafter referred to as the “First Plan”) from 2014 to 2016 in accordance with the decision-making arrangements of the Party Central Committee and the State Council.

The second phase of the special education promotion plan (2017-2020) (hereinafter referred to as the "second phase plan") will intensify efforts to promote the reform and development of special education, and continuously increase the level of

6 http://www.chinanews.com/sh/2016/05-04/7857439.shtmlhttp://www.chinanews.com/sh/2016/05-04/7857439.shtml

33

popularization, the ability to guarantee, and the quality of education and teaching.

China’s Door Opening Wider7 Over the past five years, Xi has visited 57 countries and received more than 110 foreign heads of state.

Through his travels and diplomatic meetings, Xi has helped deepen the world's understanding of a rising China, reshaped the Asian country's new role on the world stage and offered new ways forward in tackling the most

property rights, and taking the initiative to expand imports.

The initiatives sent a strong message that China's door of opening-up will not be closed and will only open even wider, showing its resolve and sincerity to share opportunities with the rest of the world and promote common development.

Xi's speech has received wide recognition in the international community. The speech added certainty and hope to the world today, and the world needs leadership like China, said International Monetary Fund Managing Director Christine Laggard.

pressing global problems.

At a time when the world is undergoing a new round of major development, great change and profound readjustment, Xi said that humanity has a major choice to make between openness and isolation, and between progress and retrogression.

At the BFA annual conference, the president unveiled new measures for expanding reform and opening-up, including significantly broadening market access, creating a more attractive investment environment, strengthening protection of intellectual

7 http://www.ecns.cn/2018/04-10/298651.shtml

34

Resource Gallery

No. 3.

A Level-3Development Evolution

Understanding Icon’s clinical practice is best set in the framework of a 3 level evolution of clinical care just as applicable to the therapeutic process as it is modern medicine. However, in the therapeutic area of care progression up this evolutionary path has been significantly lagging compared to the development of medical care in China today.

To support communication and better understanding of our mission and tasks at Sustain2, progressive Levels of the evolution of therapeutic care are referenced as follows.

Level 1 - Traditional Practices

Prior to the 2nd Industrial Revolution of the 20th century where particularly the West benefited from the century’s marked growth in science and unprecedented investments in research and development investments, ancient cultures developed the traditions of care sometimes referenced as the medicinal practice of the ancient wisdoms. Today many such practices still serve to offer relief and cure in improved health for many health challenges.

Much of the dietary and urban wisdoms have Level 3 Application been at the foundation of effective modern pharmaceutical care. Care founded from these References traditions are referred to as Level 1 and represent

an early source of help in the evolution of care.

Internally at Sustain2 we have come to apply these 3 Levels of A healthy respect for Level 1 care and development as a useful contributions, especially when facing health communication tool across almost all challenges for which modern science has not industries touched by the growing brought significant answers, can be particularly impact of research, science and helpful. Outside of the West health care technological growth. professionals have often had to practice primarily

from Level 1 understanding and therapeutic In this document for sake of easily practices. For many children seeking care for identifying Sustain2’s consistent autism this is true. As recent researchers are interest in being able to inspire finding ties to gut inflammation being linked to the emulation, Level 3 application neurological challenges with associated with descriptions are formatted in this Autism we are reminded of how modern nutrition blue text box format. had a long heritage.

35

However too often it can be also associated with traditions old practices that are harmful and developed from a miss understanding of the primary nature of disease limited by the knowledge of a past era. This is a strong reality for most care in China for autistic kids with limited access to professional clinical care and care professional training that is primarily general in nature and consisting mostly of only 2 years of study past secondary school.

Level 2 – Modern Medicine Evidence Based Care

Since the turn of the 20th century society has begun to see the evolutionary benefit of the last 30-40 years of evidence based research in clinical care, specialization, the growth of how computational technology on diagnostic clarity, effective treatment plans and desired abilities to understand and address the challenges of disease. This has been especially true following the decade of the 90’s where extensive research followed the availability of new research data from better scanning technology, bio-science research and extensive global collaboration in the health care profession and research community.

For Autism this has allowed for much earlier detection, understanding of effective therapeutic solutions and technology resources such as the benefits of collaborative care, computer guided exercises that support the development of compensating new neuron pathways and neuro feedback from live brain scan and brain activity monitoring and mapping in QEEG. Going beyond detection and better understanding these have led to autistic patients experiencing significant life quality improvements

36

especially with a wide speciality collaboration of educated medical and therapeutic staff who have benefited from 3 to 8 years of speciality training offering a high level of science and clinical integration.

For all the benefits of Level 2 therapeutic care to say that it has been curative has only been true in limited applications and with limited therapies. Significantly helpful, guided buy measurable evidence of efficacy along with some encouraging breakthroughs, a therapist post graduate level specialty training has offered significant life changes for the better. A lot can be gained by bringing more such training and care to the China market. Yet science has continued to bring new hope.

Level 3 - ICON Health Therapeutics Regeneration Labs

The third level, Level 3, of evolution in care for ICON Therapeutics clinical services and professional training has strong promise in China. China’s limited infrastructure for health services and limited

trained staff creates an opportunity to leap frog much of Level 2 as China does not have significant legacy Level 2 infrastructure and institutionalized traditions that have the ability to get in the way.

In some ways little that is still applicable of Level 2 has to be unlearned by practicing professionals.

This holds promise for patients gaining access to new science based cures and likely well ahead of their counterparts in the West. Without legacy Level 2 systems to get in the way of reform and a growing confidence with innovation, research and quality education China’s prospects for adopting Level 3 skilled care is promising.

This also solves another problem. The demand for trained service providers to Level 2 standards is so immense in China with the general absence of Level 2 training in China that a fast adoption of Level 3 will resolve much of the professional training needs. This is because the promise of Level 3 is not just better car when it comes to the autistic child but curative care with limited after cure developmental therapeutic needs required.

37

The therapeutic Level 2 care is often a lifelong commitment to improving the quality of life for an Autistic child yet limited in addressing the cause of the child’s disease life grip. It has been known as the disease that is without a cure.

However, enough progress has been made in the science global community towards understanding Autism that we are much closer to not only understanding the nature of the disease, how AI tools can facilitate early diagnoses and more effective treatment plans but the promise for most of a cure. Stem cell therapies, bioscience Artificial Intelligence and genetic therapy resources are already leaving care givers with the cure Level 3 care experiences from clinical trials . News and research publications break new promise daily.

Early diagnostic opportunities through Level 3 research in genetic work is anticipated to soon allow detection in vitro. Permanent cure genetic and or stem cell treatments are also expected from current Level 3 research progress that will offer therapeutic care even before the child is born.

Those currently facing autism prior to Level 3 curative therapeutic care, especially when late detected or left without Level 2 therapy, are expected to experience residual symptoms following cure care that will present a need for trained Level 2 specialized multi-disciplined clinical staff for some time. A great example of curative experiences from Level 3 stem cell treatments are being reported by patients participating in Duke University clinical trials referenced in the included CNN Story by Wayne Drash, research papers and the growing crowd of social medial patient published enthusiastic reports.

With each research finding, lab and science report sharing more good news, comes what seems to be a cascade of growing commitment to research funding and treatment developments. ICON Health believes it is in its mission objectives to be a part of this promising movement in each of its clinical undertakings and not in a small or token way. But instead to build it into the care and professional training model as central through it clinic integrated regeneration research labs.

38

Resource Gallery

No. 4. Additional Portfolio Opportunities

Expanding Disruptive Interests

Additional Health Portfolio Investments Sustain2 anticipates China’s growing interest in Private-Public Partnerships and China’s encouragement of a greater private health care presence as an opportunity to expand what business

interests would benefit from relocating or expanding in China. Sustian2 projects covering a large range of commercial innovations represent an important motivation in developing good location partner relationships. s.

Beyond Icon Health & Dragon Skin 2018 Location Partner Needs

Beyond the immediate opportunity in this RFP’s selected business summaries including ICON Therapeutics the following business’s summaries introduced here includes a collection of

39

companies currently portfolio holdings held in the MedCare Investment Fund cumulative with an enterprise value in excess of 850,000,000 USD:

Caliber Biotherapeutics, LLC

Caliber Biotherapeutics, LLC is a biotechnology company with a mission to develop and commercialize protein-based therapeutics that improve outcomes for patients with cancer and other diseases. The company utilizes technological innovations in biological research, product development and manufacturing to create treatments with increased safety and effectiveness—while reducing both costs and development time.

www.caliberbio.com

Caliber Biotherapeutics，LLC 是一家生物技术公司，致力于开发和商业化基于蛋白质的疗法，改善癌症 和其他疾病患者的预后。该公司利用生物研究，产品开发和制造方面的技 术创新，创造更高安全性和有效性的治疗方案，同时降低成本和开发时 间。

CeloÒNova Biosciences

CeloNova Biosciences develops, manufactures and markets a family of products based upon the unique properties of PolynzeneÒ-F, pairing polymer science innovation with cutting edge devices. The company’s products are used by physicians across the globe to improve patient outcomes in the fields of vascular intervention and embolization.

www.lonova.com

CeloNova Biosciences

基于 Polynzene-F 的独特性能开发，制造和销售一系列产品，将聚合物科学创 新与尖端设备相结合。该公司的产品被全球的医生用于改善血管介入和栓塞 领域的患者结果。

digiChart Focused Technology for Specialty Care

digiChart is dedicated to improving women’s healthcare by providing EHR and practice management system solutions specifically engineered for OB-GYNs.

www.digichart.com

40

digiChart 针对专科护理的专注技术 digiChart 致力于通过提供专为 OB-GYNs 设计的 EHR 和实践管理系统解决 方案来改善女性医疗保健

EviCore Healthcare Innovation Solutions

EviCore Healthcare is a medical cost management company, saving money for health plans and people by improving patient care.

www.evicore.com

G-CON Manufacturing

G-Con is dedicated to revolutionizing the biomanufacturing industry by providing comprehensive GMP manufacturing solutions that are flexible, less expensive to build and maintain, and easier to operate than any existing solution on the market.

www.gconbio.com

41

Gradalis

Gradalis is a vertically integrated biotechnology company committed to developing core technologies poised to deliver therapeutics that offer safer and more effective treatments for cancer.

www.gradalisinc.com

ICA The Interoperability Experts

ICA’s CareAlign platform powers interoperability and intelligence solutions that leverage existing technologies to connect care teams across healthcare enterprises.

www.ica-carealign.com

MindCare Solutions

MindCare Solutions collaborates with our healthcare partners to optimize individual patient care, incorporating telemedicine technologies, and a national behavioral health provider network in order to improve healthcare outcomes and reduce the overall cost of medical care. MindCare Solutions also provides the type of individual therapeutic and social networking resource that promotes individual health improvement.

www.mindcaresolutions.com

42

Molecular Sensing Illuminating Biological Interactions

Molecular Sensing (MSI) is an early-stage life science company dedicated to commercializing a new, game-changing molecular interaction biosensor technology, Back-Scattering Interferometry (BSI). BSI addresses unmet needs in pharmaceutical drug discovery and development, biomedical research and diagnostics by overcoming the limitations of Surface Plasmon Resonance (SPR) and Isothermal Titration Calorimetry (ITC), while combining their advantages in a single, synergistic platform.

www.molsense.com

OccuSystem Services, Inc.

OccuSystems Services, Inc. (OSI), an Occupational Health Benefit Management Company driven to provide access to the highest-quality healthcare available and the most time-efficient protocols in order to appropriately maintain injuries and return employees to the workplace as quickly as possible. OSI will significantly reduce the cost of work related injuries while improving both the employer’s productivity and enhancing the patient’s experience while dealing with the injury. www.occusystem.com

43

OutPatient Imaging Affiliates, LLC (OIA)

Outpatient Imaging Affiliates (OIA) partners with healthcare providers, including academic teaching hospitals, hospital medical centers, and local radiology practices to develop and deploy strategies designed to recapture market share on behalf of its partners.

www.oiarad.com

Refocus Group

Refocus Group is a medical device company engaged in the research and development of treatments for human vision disorders, seeking to become the surgical standard of care for presbyopia, primary open-angle glaucoma and ocular hypertension worldwide.

www.refocus-group.com

44

Seno Medical Instruments, Inc.

Seno Medical commercializes a new modality in cancer screening and diagnosis called opto-acoustic imaging. Unlike most screening techniques that rely on anatomical imaging, Seno’s goal is to bring functional imaging that can detect angiogenesis to the marketplace.

www.senomedical.com

Strike Bio, Inc.

This organization primarily operates in the Biological Research business/industry within the Engineering, Accounting, Research, and Management Services sector.

This organization has been operating for approximately 5 years. Strike Bio is estimated to generate $390,000 in annual revenues and employs approximately 5 people at this single location.

Valor Biotherapeutics, LLC

Valor Biotherapeutics, LLC engages in the clinical development and commercialization of monoclonal antibody-based therapeutics to treat cancer.

Its products include IGN002 that includes an anti-CD20 monoclonal antibody attached to IFN through stable peptide linker system; IGN001 that comprises an anti-Her2 monoclonal antibody attached to IFN through stable peptide linker system; and IGN003 that includes a monoclonal antibody directed towards a validated multiple myeloma target attached to IFN through stable peptide linker system.

www.valorbiotherapeutics.com

45

46

Resource Gallery

No. 6. Public-Private Partnership Western models of clinical care have to be adapted to Chines mix of private and public payment for health systems in ways that are significantly divers from the West. A significant role of a China location partner beyond assisting with incentives to help offset the costs of locating and establishing operations in China include assisting in finding new ways to navigate policy and the regulatory environment in a private-public partnership model that can assure economic viability, especially during the early years of establishing a new level of care and public awareness of both the health challenges that Sustain2 operations as well as how to get care costs support available through public assistance.

Historically key to public-private partnership success in health care has been the strength the public sector has to direct is health expenditures into the private partner so as to assure the base revenue required to build strong solutions.

The term ‘public-private partnership’ (PPP) describing a relationship in which public and private resources are blended to achieve a goal or set of goals is increasingly judged to be mutually beneficial both to the private entity and to the public.

PPPs that incorporate—in innovative and creative ways—the deployment and use of government led initiatives have the power to improve the services that matter most to city and providence communities: education, healthcare in addition to transportation, economic development, public safety, and social services provide a strategic development framework for Sustain2. There is a growing acceptance in China that rather than simply cut back on these services in the face of budget deficits, or plow forward alone with aggressive development objectives, governments can work This has been modeled on a global basis as illustrated in a European the Living Labs PPP of city governments and private companies aims to create a user-driven open innovation eco-system where users live, work, study, play and entertain in a progressive multi waves of combined

47

Resource Gallery

No. 6. Supplemental Picture Gallery

48

AirShip Material Science Targets – leading edge atomic precision manufacturing. During this century, scientists and engineers from BAE Systems and The University of Glasgow envisage that small Unmanned Air Vehicles (UAVs) could be ‘grown’ in large-scale labs through chemistry, speeding up evolutionary processes and creating aircraft in weeks, rather than 8 years.

AirShip R&D. With new materials, purposing and weight to energy storage technology comes the opportunities for new 9 design and use cases.

8 http://futuristicnews.com/bae-systems-plans-to-grow-armies-of-drones-in-giant-tubs-ofchemicals/ 9 https://youtu.be/Re29lqCEtpc

49

Flexible solar panel production cells designed to be added to flight surfaces continues to increase in efficiency and increases the number of applications that AirShip can function 100% on Solar production for more and more of its models in some cases with real time production exceeding maximum energy demand flight characteristics by 800%. 10

10 Solar Impulse 2 made history June 23

50

NORWEGIAN MARINE & ENERGY CENTER (NMEC) NMEC represents a good benchmark facility to demonstrate the scope of a marine development and port security services center for HyperSub development and HyperSub services deployment. 11

11 http://unitechrndcenter.com

51

52

53

Tactical Light Operator Suit, also known as the "Iron Man" suit, in 201812

12 https://www.slashgear.com/u-s-militarys-talos-project-tapped-hollywood-designer06336534/

54

13

The blueprint for the Tactical Assault Light Operator Suit (TALOS) would include an exoskeleton to allow a soldier to carry heavy equipment, built-in computing power, beefed up protection to stop bullets and a system to monitor vital signs, and address data gathering for a soldier or first responder is part of the step into the future of protective clothing industry.

Beyond advanced armor, situational awareness, command and control computers, power management systems, and enhanced mobility exoskeletons might also employ "liquid armor," that transform into a solid if a magnetic or electrical charge was applied.14

13 http://www.businessinsider.com/russia-just-showed-off-new-stars-wars-combat-suit-2017-6 14 http://www.scmp.com/news/world/article/1330431/us-army-developing-iron-man-bodyarmour-soldiers-future

55

A picture showing Jia Jia, with the red backpack, doing outdoor training in Guangzhou, Guangdong province hands tether tied to the adult walker, April 27, 2016.

Courtesy of Da Ba

56

Table of Contents REQUEST FOR PROPOSAL ..................................................................................................................... 1 I.

SUMMARY ................................................................................................................................... 2 REQUEST FOR PROPOSAL ............................................................................................................................... 2 INVESTMENT ECONOMICS .............................................................................................................................. 2 SUSTAIN2 PORTFOLIO INITIATIVES ................................................................................................................... 2 ICON HEALTH & EDUCATION .......................................................................................................................... 3 TRANSPORTATION ........................................................................................................................................ 3 LEVEL 3 ...................................................................................................................................................... 4 Local Partner Capital Contributions ..................................................................................................... 4 Non-Monetary Considerations ............................................................................................................. 4

OUTLINE ............................................................................................................................................... 5 II. BACKGROUND ................................................................................................................................. 6 SUSTAIN2 ASSETS ......................................................................................................................................... 6 LOCATION PARTNERS .................................................................................................................................... 6 PURPOSE .................................................................................................................................................... 6 SUSTAIN2’S MISSION .................................................................................................................................... 6 AHEAD FOUNDATION .................................................................................................................................. 6 III. BUSINESS REVIEW ........................................................................................................................... 8 ICON THERAPEUTICS ............................................................................................................................ 8 Icon Therapeutics Mission ................................................................................................................... 8 Science Applied .................................................................................................................................... 9 US Supervisory Support. ..................................................................................................................... 10 Genetic Therapy Frontiers .................................................................................................................. 11 LONGEVITY THERAPEUTICS ........................................................................................................................... 11 Emerging Market Opportunities ........................................................................................................ 12 CAPITAL RESOURCES ................................................................................................................................... 12 THE ICON THERAPEUTICS LOCATION NUMBERS ................................................................................................ 13 HYPER-SUB ......................................................................................................................................... 15

57

Research & Development, Production and Port & Border Water Surface & Subsurface Protection .. 17 DRAGON SKIN .................................................................................................................................... 18 Dragon Skin Background ................................................................................................................... 18 AIRSHIP .............................................................................................................................................. 20 IV. LOCATION ..................................................................................................................................... 24 FACILITIES ................................................................................................................................................. 24 ICON THERAPEUTICS ................................................................................................................................... 24 DRAGON SKIN ............................................................................................................................................ 24 INCENTIVES ............................................................................................................................................... 25 RESOURCE GALLERY ........................................................................................................................... 27 NO. 1. THE CASE FOR CHINA ........................................................................................................................ 27 China’s Reform Opportunity .............................................................................................................. 27 NO. 2.THE NATURE OF CHINA’S NEED ........................................................................................................... 29 China’s Reform Opportunity .............................................................................................................. 29 THE SIZE AND SCOPE OF NEED ...................................................................................................................... 30 THE NATURE OF THE NEED ........................................................................................................................... 30 JIA’S STORY ............................................................................................................................................... 31 The Flexner Report ............................................................................................................................. 32 Science Foundations .......................................................................................................................... 32 China’s Door Opening Wider ............................................................................................................. 34 NO. 3. A LEVEL-3DEVELOPMENT EVOLUTION ................................................................................................. 35 Level 1 - Traditional Practices ............................................................................................................ 35 Level 2 – Modern Medicine Evidence Based Care .............................................................................. 36 Level 3 - ICON Health Therapeutics Regeneration Labs ..................................................................... 37 NO. 4. ADDITIONAL PORTFOLIO OPPORTUNITIES ............................................................................................. 39 NO. 6. PUBLIC-PRIVATE PARTNERSHIP ........................................................................................................... 47 NO. 6. SUPPLEMENTAL PICTURE GALLERY ...................................................................................................... 48

58